Switching HIV treatment to test effects on aging
This study tests whether switching to a new HIV medication combination (doravirine/islatravir) can improve markers of aging in people with well-controlled HIV. If you join, you would either stay on your current HIV medicines or switch to the new combination, and the study will compare how your body's aging markers change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and have been on HIV medications for at least 2 years.
- You've been on your current HIV medicines for at least 6 months.
- Your HIV viral load is under 50 copies/mL (meaning effectively suppressed).
- You are not pregnant or planning to become pregnant during the study.
- You do not have active hepatitis B or C, or other serious conditions like certain cancers or liver disease.
- You do not have a history of resistance to doravirine or other reasons your viral load might increase.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This study tests switching your current HIV medicines to a once-daily pill combining doravirine, tenofovir, and lamivudine, specifically for people whose virus has a past M184V mutation but is now well controlled.
This study looks at switching your current HIV medication to a two-drug combination pill called dolutegravir/lamivudine (DTG/3TC). The goal is to see if this simpler regimen is safe and effective for people who are also on opioid agonist therapy. If you qualify, you may have the option to switch to a potentially easier HIV treatment while continuing your opioid therapy.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
Hear when a new Epigenetic Aging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.